天然产物研究与开发 ›› 2026, Vol. 38 ›› Issue (6): 1314-1327.doi: 10.16333/j.1001-6880.2026.6.016 cstr: 32307.14.1001-6880.2026.6.016

• 数据研究 • 上一篇    下一篇

基于质谱分析和网络药理学的伊贝母总生物碱治疗肺纤维化作用及机制研究

牌铭欣1,吴叶鑫1,谢慧敏2,谢慧淦2,明吉措姆3*,叶本贵1,4*   

  1. 1四川大学华西药学院,成都 610041;2京都念慈菴总厂有限公司,香港 999077;3西藏藏医药大学,拉萨 850002;4西藏大学,拉萨 850000
  • 出版日期:2026-06-26 发布日期:2026-06-24
  • 基金资助:
    西藏自治区科技计划(XZ202301ZY0009G,XZ202401YD0022,XZ202201ZD0001G01/06);藏医药“十四五”规划内涵建设项目(2023ZYYGH02)

Effect and mechanism of total alkaloids from Fritillariae Pallidiflorae Bulbus in the treatment of pulmonary fibrosis based on mass spectrometry analysis and network pharmacology

PAI Ming-xin1,WU Ye-xin1,XIE Hui-min2,XIE Hui-gan2,Mingjicuomu3*,YE Ben-gui1,4*   

  1. 1West China School of Pharmacy,Sichuan University,Chengdu 610041,China;2Nin Jiom Medicine Manufactory (H.K.) Limited,Hong Kong 999077,China;3Xizang University of Tibetan Medicine,Lhasa 850002,China;4Tibet University,Lhasa 850000,China.
  • Online:2026-06-26 Published:2026-06-24

摘要:

探究伊贝母总生物碱(total alkaloids of Fritillariae Pallidiflorae Bulbus,FPB-TA)抑制肺纤维化(pulmonary fibrosis,PF)的有效成分及作用机制。本研究利用HPLC-Q-TOF-MS/MS和LC-MS/MS技术对FPB-TA进行成分分析。通过TCMSP等数据库筛选伊贝母治疗PF的潜在靶点;利用STRING数据库构建蛋白互作网络;对核心靶点进行GO生物功能注释和KEGG通路富集;分子对接技术模拟伊贝母中生物碱成分与关键靶点的结合能力。此外,通过转化生长因子β1(transforming growth factor-beta 1,TGF-β1)诱导构建A549细胞的PF体外模型,并利用Western blot和天狼星红染色等方法验证FPB-TA对PF的治疗作用及机制验证。结果表明,经质谱分析鉴定出24类241个化合物,9个生物碱的含量占总生物碱含量的55.362%。网络药理学共获得交集靶点115个,蛋白质相互作用分析筛选后获得22个靶点,181条相互作用边,KEGG富集涉及Ras相关蛋白1(Ras-related protein 1,RAP1)信号通路、癌症通路、丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)信号通路等,综合考虑选取RAP1信号通路进行研究。筛选出活性成分中的生物碱成分与RAP1信号通路中的关键蛋白RAP1B进行分子对接,结果显示活性成分与关键蛋白结合力良好。体外实验表明,FPB-TA可以有效地改善TGF-β1刺激的A549细胞的胶原沉积,并且可以有效抑制RAP1B蛋白的表达。本研究揭示了FPB-TA中的化学成分,并探索了其延缓PF潜在的分子机制,为后续深入探讨其作用机制提供理论依据和研究方向。

关键词: 伊贝母, 生物碱, A549细胞, 网络药理学, 肺纤维化

Abstract:

This study aims to investigate the effective components and mechanisms of action of total alkaloids of Fritillariae Pallidiflorae Bulbus (FPB-TA) in inhibiting pulmonary fibrosis (PF). HPLC-Q-TOF-MS/MS and LC-MS/MS techniques were used to analyze the constituent of FPB-TA. Potential targets for the treatment of PF were screened using databases such as TCMSP; Protein-protein interaction network was constructed using the STRING database; GO biofunctional annotation and KEGG pathway enrichment were performed on core targets; Molecular docking techniques were used to simulate the binding ability of alkaloid components in Fritillariae Pallidiflorae Bulbus to key targets. A transforming growth factor-beta 1 (TGF-β1)-induced PF in vitro model of A549 cells was constructed. Western blot and Sirius red staining were used to verify the therapeutic effect and mechanism of FPB-TA on PF. Mass spectrometry analysis identified 241 compounds in 24 classes, with nine alkaloids accounting for 55.362% of the total alkaloid content. Network pharmacology yielded 115 intersection targets, and protein-protein interaction analysis screened 22 targets with 181 interaction edges. KEGG enrichment involves the Ras-related protein 1 (RAP1) signaling pathway, cancer pathway, mitogen-activated protein kinase (MAPK) signaling pathway, etc. The RAP1 signaling pathway was selected for further study. Molecular docking was performed between the alkaloid components of the active ingredient and the key protein RAP1B in the RAP1 signaling pathway, showing good binding affinity between the active ingredient and the key protein. In vitro experiments showed that FPB-TA can effectively improve collagen deposition in TGF-β1-stimulated A549 cells and effectively inhibit RAP1B protein expression. This study revealed the chemical components of FPB-TA and explored its potential molecular mechanism for alleviating PF, providing a theoretical basis and research direction for further in-depth exploration of its mechanism of action.

Key words: Fritillariae Pallidiflorae Bulbus, alkaloid, A549 cell; network pharmacology, pulmonary fibrosis

中图分类号:  R932